title: Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation.
abstract: OBJECTIVE
  To determine factors predictive for leflunomide drug survival in an outpatient population with rheumatoid arthritis in a setting of care-as-usual.
  
  
  METHODS
  A standard dataset was collected from medical records of consecutive outpatients on leflunomide treatment for rheumatoid arthritis between January 2000 and June 2003. The dataset consisted of patient, disease and treatment characteristics at the start of leflunomide treatment, and data on leflunomide use.
  
  
  RESULTS
  Leflunomide was started in 279 patients and 173 patients (62.0%) withdrew from treatment during follow-up. From univariate analysis, concomitant systemic corticosteroid use [hazard ratio (HR) (95% confidence interval) 1.35 (1.00, 1.83)] and an erythrocyte sedimentation rate <35 mm h(-1)[HR 1.38 (1.01, 1.88)] at start of leflunomide were found to be predictive for better leflunomide survival. Furthermore, the attending rheumatologist was correlated with leflunomide drug survival. Hazard ratios varied, depending on the individual rheumatologist, from 0.60 to 2.66. Multivariate analysis suggested attending rheumatologist (HR varying from 0.54 to 2.30 depending on the individual rheumatologist), concomitant systemic corticosteroid use [HR 1.58 (1.14 2.21)] and erythrocyte sedimentation rate <35 mm h(-1)[HR 1.42 (1.03, 1.96)] at start of leflunomide to be associated with leflunomide survival.
  
  
  CONCLUSIONS
  Concomitant systemic corticosteroid use, erythrocyte sedimentation rate at the start of treatment and attending rheumatologist were found to be predictive for leflunomide survival. Information on these predictors at the start of leflunomide therapy may offer information on which patients are at an increased risk of withdrawal from leflunomide. Whether this information leads to optimization of leflunomide treatment outcomes remains to be studied.
authors.affiliation: Department of Clinical Pharmacy & Pharmacology, Medisch Centrum Leeuwarden, Leeuwarden, the Netherlands. e.n.van.roon@znb.nl
authors.forename: E N
authors.initials: EN
authors.lastname: van Roon
authors.forename: M
authors.initials: M
authors.lastname: Hoekstra
authors.forename: H
authors.initials: H
authors.lastname: Tobi
authors.forename: T L Th A
authors.initials: TL
authors.lastname: Jansen
authors.forename: H J
authors.initials: HJ
authors.lastname: Bernelot Moens
authors.forename: J R B J
authors.initials: JR
authors.lastname: Brouwers
authors.forename: M A F J
authors.initials: MA
authors.lastname: van de Laar
mesh_terms: D000368:Aged; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007555:Isoxazoles; D000077339:Leflunomide; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D013997:Time Factors
chemical_list: D018501:Antirheumatic Agents; D007555:Isoxazoles; D000077339:Leflunomide